President Donald Trump said in a CNBC interview that the United States will impose an initially “small” tariff on imported pharmaceuticals, then lift the duty to 150% within 12 to 18 months and eventually to 250%. The measure, he said, is aimed at pushing drug manufacturing back to the United States. The tariff threat follows a Section 232 national-security investigation into the resilience of the drug supply chain. While current U.S. and European Union rules keep pharma duties at zero, the administration argues that higher levies are needed to reduce reliance on overseas production. Several drugmakers have already announced additional domestic investment, with AstraZeneca committing about $50 billion to expand its U.S. footprint. Trump added that a separate tariff plan for semiconductors and chips will be unveiled “within the next week or so,” but he offered no figures. Industry groups have warned that sweeping duties on either sector could raise costs for consumers and disrupt supply chains.